What Is an ECMO Circuit and How Does It Work?

An ECMO circuit is essentially a temporary artificial heart-lung machine that sits outside the body, drawing blood out through large tubes, adding oxygen and removing carbon dioxide, then pumping the blood back in. At its core, the circuit has four main components: a mechanical blood pump, a gas-exchange device (the oxygenator), a heat exchanger, and the tubing that connects everything together.¹ The concept grew out of cardiopulmonary bypass technology used in open-heart surgery, but ECMO is designed to run for days, weeks, or occasionally even longer, supporting patients whose hearts or lungs have failed so severely that conventional treatments cannot keep them alive.

The Four Core Components

Every ECMO circuit, no matter how simple or complex, is built around the same backbone. The blood pump creates the driving force that pulls blood from the patient and pushes it through the circuit. Modern circuits almost universally use centrifugal pumps, which spin blood using a rotating impeller rather than squeezing it through rollers. The oxygenator does the work the lungs normally handle: fresh oxygen diffuses into the blood across a thin membrane while carbon dioxide diffuses out. The heat exchanger keeps blood at the right temperature, since traveling through meters of plastic tubing outside the body would cool it quickly. And the tubing itself, typically made of polyvinyl chloride or silicone, ties all of these pieces into a continuous loop.

Beyond these essentials, most circuits also include blood-flow and pressure monitors, sensors that continuously measure how much oxygen is in the blood, access ports for drawing labs or giving medications, and sometimes a bridge connector that links the two main limbs of tubing together so the circuit can be briefly isolated from the patient if needed.¹

Two Configurations for Two Problems

ECMO comes in two main flavors, and the choice depends on what organ has failed. Veno-venous (VV) ECMO is used when the lungs are the problem but the heart is still pumping well. Blood is drained from a large vein, run through the circuit for gas exchange, and returned to another vein. The patient’s own heart still does all the pumping to the rest of the body. Veno-arterial (VA) ECMO is used when the heart itself is failing, sometimes along with the lungs. Blood is drained from a vein but returned to an artery, so the circuit is effectively doing the heart’s job of delivering oxygenated blood to the body’s tissues.²

This distinction matters beyond the operating room. VV ECMO is a gentler setup because the blood stays in the venous system; there is no arterial cannula that could compromise blood flow to a limb. VA ECMO provides more powerful support but introduces complications unique to having a large catheter sitting in a major artery, which we will get to shortly.

Getting Blood In and Out

The large catheters used to connect the patient to the circuit are called cannulas, and where they go is one of the most consequential decisions the surgical team makes. For VA ECMO, cannulation can be “peripheral,” meaning the tubes are placed into the femoral vein and artery in the groin, or “central,” meaning the cannulas are sewn directly into the heart’s chambers and the aorta during open surgery. Central cannulation provides better drainage and avoids certain complications, but it requires a sternotomy, so it is mostly used in patients who are already in the operating room after cardiac surgery.³

For VV ECMO, newer dual-lumen cannulas allow both drainage and return through a single catheter placed in the neck, which can make it easier for patients to sit up, participate in physical therapy, and in some cases even come off the ventilator while still on ECMO.³ The idea of an awake, mobile patient connected to a machine that is breathing for them sounds counterintuitive, but it has become an increasingly common goal in centers experienced with ECMO.

Inside the Oxygenator

The oxygenator is the component that most directly replaces the lung. Modern oxygenators use hollow-fiber membranes made of polymethylpentene (PMP), a material chosen because it resists plasma leakage. Blood flows on one side of thousands of tiny hollow fibers while a mixture of oxygen and air (called sweep gas) flows through the inside of the fibers. Gas exchange happens across the fiber walls by diffusion, just as it does across the thin walls of lung alveoli, except the membrane is engineered rather than biological.

Over time, proteins, platelets, and red blood cells can accumulate on the membrane surface, forming a fibrous layer that increases resistance to blood flow and reduces the oxygenator’s ability to transfer gases.⁴ In one study tracking patients on ECMO, roughly one in ten required the oxygenator to be swapped out after about a week and a half because of this buildup. This is one of the reasons ECMO teams monitor the oxygenator’s performance continuously: a gradual rise in the pressure needed to push blood through, or a decline in the oxygen level of blood leaving the device, signals that the membrane is deteriorating.

The Centrifugal Pump and Red Blood Cell Damage

The pump is the engine of the circuit, and virtually all modern ECMO systems use centrifugal designs in which a magnetically levitated or magnetically coupled impeller spins at thousands of revolutions per minute. Blood enters the center of the spinning cone and is flung outward, generating the pressure needed to keep it moving through the circuit at flow rates that can reach several liters per minute.

The tradeoff is mechanical stress on blood cells. Red blood cells passing through the pump experience shear forces, and some fraction of them rupture, a process called hemolysis. Computational modeling of a centrifugal ECMO pump estimated a hemolysis index of about 1.3%, with the pump impeller responsible for roughly 84% of the total cell damage within the pump.⁵ That may sound modest, but over days or weeks of continuous operation, the cumulative loss of red blood cells can become clinically meaningful, requiring transfusions. Newer pump designs focus on reducing these shear forces, and the trend toward smaller, more refined impellers has helped, but hemolysis remains an inherent cost of pushing blood through mechanical hardware.

Temperature Management

Blood cools as it travels through tubing and the oxygenator, so a heat exchanger is necessary to warm it before returning it to the patient. In most designs, the heat exchanger is integrated into or immediately adjacent to the oxygenator. It works by circulating warm water through channels that run close to the blood path, allowing heat to transfer without direct contact.⁶ The same system can be used in reverse to actively cool patients when therapeutic hypothermia is desired, for instance after cardiac arrest. The ability to precisely control body temperature is one of the underappreciated capabilities of an ECMO circuit.

Anticoagulation and the Clotting Balancing Act

Blood was not designed to flow through plastic. The moment it contacts the circuit’s synthetic surfaces, the clotting cascade activates. Without blood thinners, clots would form throughout the circuit within minutes, potentially blocking the oxygenator or embolizing back into the patient. This is why every ECMO run requires anticoagulation, and managing it is one of the most difficult day-to-day tasks for the care team.

Unfractionated heparin remains the most widely used anticoagulant for ECMO. It is familiar, fast-acting, and reversible, but keeping it in the right range is notoriously fiddly. Teams typically monitor it using activated partial thromboplastin time or activated clotting time, though newer assays are gaining attention for their reliability.⁷ Too little heparin and clots form in the circuit; too much and the patient bleeds. There is no comfortable middle ground, just a narrow target that shifts as the patient’s own clotting factors change from day to day.

For patients who develop an immune reaction to heparin, called heparin-induced thrombocytopenia, the direct thrombin inhibitor bivalirudin is an important alternative. Retrospective studies comparing bivalirudin to heparin have found similar rates of bleeding and clot formation between the two drugs. One advantage bivalirudin consistently shows is more predictable dosing: patients on bivalirudin spent a larger portion of time within their target anticoagulation range and needed far fewer dose adjustments.⁸ Still, bivalirudin is more expensive and less widely available, so heparin remains the default at most centers, with bivalirudin reserved for patients who truly cannot tolerate it.⁹

Bleeding That Is Not About the Blood Thinner

Anticoagulation is not the only reason ECMO patients bleed. The shear forces inside the circuit damage von Willebrand factor, a large sticky protein that is essential for platelets to plug wounds. Almost all patients on ECMO develop what is called acquired von Willebrand syndrome, often within hours of being connected to the circuit.¹⁰ The high shear unravels the protein, rendering it less functional, and platelets themselves also become sluggish in their response. The good news is that this bleeding tendency resolves quickly once ECMO is removed. In one study, the clotting abnormality recovered within three hours in the majority of patients after the circuit was disconnected, and in everyone within a day.¹⁰ The bad news is that while a patient is on ECMO and simultaneously receiving blood thinners, both problems stack, making bleeding one of the most common and dangerous complications.

Limb Ischemia in VA ECMO

When a large arterial cannula is placed in the femoral artery for VA ECMO, it can obstruct blood flow to the leg on that side. Think of it like partially blocking a garden hose: everything downstream gets less flow. Limb ischemia is a well-recognized complication, and one study found that about a third of patients who did not receive a small extra catheter to perfuse the leg downstream of the cannula developed signs of ischemia.¹¹

To prevent this, many centers now place a small distal perfusion catheter at the time of cannulation, which diverts a portion of the oxygenated blood down toward the foot. When ischemia does develop and a perfusion catheter is placed as a rescue measure, it can still salvage the limb in most cases.¹² The practice of prophylactic distal perfusion has become something of a dividing line between ECMO centers: some place it in every femoral VA ECMO patient, while others take a wait-and-see approach, monitoring the limb with near-infrared spectroscopy and intervening only if trouble appears.

Air in the Circuit

Air entering the ECMO circuit is one of the most feared emergencies because air bubbles delivered into the arterial system can cause strokes or other catastrophic embolism. In a VA circuit, where blood is returned to an artery, even a small volume of air that passes through the oxygenator could reach the brain. Fortunately, multiple layers of protection exist. Bubble detectors placed near the return cannula alarm when air is detected, and the oxygenator itself traps and slowly vents small amounts of gas. In bench testing, as little as one milliliter of air injected into the circuit at high pump speeds was enough to trigger a bubble alarm, and larger volumes caused the pump to lose flow entirely as the air pocket disrupted the centrifugal mechanism.¹³

When air does enter a real clinical circuit, the pump can “airlock,” meaning the centrifugal impeller loses its prime and stops moving blood. This is an emergency requiring immediate intervention. Techniques to de-air the circuit and restore flow include briefly running the pump backward (called backflush) or swapping the entire circuit. One center reported that in over a decade of ECMO use, only four out of 116 patients experienced significant air events, and in all four cases the source was identified, flow was restored, and three of four patients eventually left the hospital.¹⁴ Rare, but when it happens, every second counts.

Infection Risk at the Cannula Site

Large-bore cannulas sitting in blood vessels for days or weeks are a breeding ground for infection, much like central venous catheters in general ICU patients but larger and harder to keep sterile. In a multicenter European study, the pathogens causing cannula-related infections were predominantly gut bacteria, skin organisms, and enterococci, and about 42% of infection episodes involved more than one organism.¹⁵ Infections tend to show up after about ten days on ECMO, and longer ECMO runs and diabetes are independently associated with higher risk.¹⁶ Daily site care, strict sterile technique during any circuit access, and a push to wean ECMO as soon as possible are the main defenses.

Weaning Off ECMO

Getting a patient off ECMO is its own complex process. For VV ECMO, the key test is whether the patient’s lungs can handle gas exchange on their own. The team turns off the sweep gas flowing through the oxygenator, which eliminates the circuit’s ability to add oxygen or remove carbon dioxide, while leaving the pump running so blood still circulates. If the patient can maintain acceptable blood gases with the ventilator doing the work for at least a couple of hours, the team considers removing the cannulas.¹⁷ For VA ECMO, weaning is trickier because the heart also needs to demonstrate it can sustain adequate blood pressure and cardiac output as circuit flow is gradually reduced. Echocardiography plays a central role during VA wean trials to watch how the heart responds in real time.

Pediatric and Neonatal Circuits

Children and especially newborns present a unique engineering challenge: their total blood volume may be only a few hundred milliliters, so the volume of blood needed to fill the circuit (the prime volume) becomes a much larger fraction of the child’s own circulation. A standard adult circuit primed with 260 milliliters of fluid would significantly dilute a neonate’s blood, requiring donor blood to be added just to fill the tubing. Miniaturized circuits with prime volumes as low as 99 milliliters have been developed, allowing some pediatric ECMO runs to start without donor blood at all and to be set up faster.¹⁸ The trend continues toward even smaller, more biocompatible components that reduce both the amount of foreign surface the blood contacts and the risk of hemolysis and clotting in tiny patients.¹⁹

What ECMO Costs

ECMO is one of the most resource-intensive therapies in modern medicine. The equipment itself, the oxygenator, pump, tubing, and monitoring hardware, is only a fraction of the total expense. Hospital cost breakdowns consistently show that the largest share goes to staffing: perfusionists, ICU nurses, surgeons, and intensivists. In one analysis from Norway, personnel accounted for about 82% of total hospital costs during an ECMO admission, with the ECMO procedure itself adding an average of roughly $67,000 in ICU costs per patient.²⁰ Other cost studies paint a similar picture: the consumable ECMO hardware represents somewhere between 10% and 20% of total costs, while ICU days, blood products, and personnel dominate the bill.²¹ This is one reason ECMO remains concentrated in large academic medical centers rather than available at every hospital. It requires not only the hardware but around-the-clock expert staffing.

Life After ECMO

Surviving ECMO is not the same as returning to normal life. In a qualitative study of adult ECMO survivors, every participant described significant physical challenges afterward, about two-thirds reported at least one lasting psychological or cognitive difficulty, and a quarter were unable to return to work.²² Muscle wasting from prolonged immobility, nerve damage from cannulation, anxiety, depression, and post-traumatic stress are all documented consequences. Some patients recall terrifying hallucinations or delirium during their time on the circuit, and the psychological scars can persist long after the physical ones heal. ECMO centers increasingly recognize that follow-up care, including rehabilitation and mental health support, is not optional but part of the treatment itself.

How ECMO Evolved to Its Current Form

ECMO’s roots trace to the cardiopulmonary bypass machines that made open-heart surgery possible in the 1950s. Those early machines were designed for hours of use, not days. It was not until the early 1970s that Robert Bartlett and others began adapting the technology for prolonged bedside support, and the first successful ECMO runs in human patients followed.²³ Over the past fifty years, each generation of hardware has improved: oxygenators moved from silicone rubber to PMP hollow-fiber membranes, roller pumps gave way to centrifugal designs, and circuits shrank in both size and prime volume.²⁴ The COVID-19 pandemic pushed ECMO use to unprecedented levels and demonstrated that some patients could remain on support for more than a year while waiting for lung transplantation, a scenario that would have been unthinkable with earlier equipment.²³ The engineering challenge now is not whether prolonged support is possible but how to make the circuit biocompatible enough that weeks or months of use do not extract such a heavy toll in blood damage, clotting, and infection.

1
PubMed Central. Extracorporeal membrane oxygenation circuitry
2
PubMed. The physiology of extracorporeal membrane oxygenation: The Fick principle
3
PubMed Central. Cannulation strategies in adult veno-arterial and veno-venous extracorporeal membrane oxygenation: Techniques, limitations, and special considerations
4
PubMed Central. Efficiency in extracorporeal membrane oxygenation-cellular deposits on polymethylpentene membranes increase resistance to blood flow and reduce gas exchange capacity
5
International Journal of Fluid Engineering. Evaluation of hemolysis in centrifugal blood pump of ECMO system based on CFD-DPM method
6
Scientific Reports. Novel heat exchanger in extracorporeal circuit: technical and biological feasibility
7
JHLT Open. Anticoagulation Management During ECMO: Narrative Review
8
ASAIO Journal. Comparison of Bivalirudin Versus Unfractionated Heparin for Anticoagulation in Adult Patients on Extracorporeal Membrane Oxygenation
9
ASAIO Journal. Evaluation of Systemic Heparin Versus Bivalirudin in Adult Patients Supported by Extracorporeal Membrane Oxygenation
10
The Journal of Heart and Lung Transplantation. Acquired von Willebrand syndrome and impaired platelet function during venovenous extracorporeal membrane oxygenation
11
PubMed. Arterial protocol including prophylactic distal perfusion catheter decreases limb ischemia complications in patients undergoing extracorporeal membrane oxygenation
12
PubMed Central. Distal Perfusion Cannulation and Limb Complications in Venoarterial Extracorporeal Membrane Oxygenation
13
PubMed Central. Prevention of Air Embolism in Extracorporeal Membrane Oxygenation Systems: An In Vitro Study on Protection of Central Venous Catheter Lumen
14
PubMed. Management of Circuit Air in Extracorporeal Membrane Oxygenation: A Single Center Experience
15
PubMed Central. Characteristics and outcomes of ECMO cannula-related infections: a European multicenter retrospective study
16
ASAIO Journal. Extracorporeal Membrane Oxygenation Cannula–Related Infections: Epidemiology and Risk Factors
17
PubMed Central. Duration of sweep gas off trial for weaning from venovenous extracorporeal membrane oxygenation
18
PubMed. Early experience with low-prime (99 ml) extracorporeal membrane oxygenation support in children
19
PubMed. Device updates in pediatric and neonatal ECMO
20
European Journal of Cardio-Thoracic Surgery. Cost of extracorporeal membrane oxygenation: evidence from the Rikshospitalet University Hospital, Oslo, Norway
21
PubMed Central. Hospital Costs of Extracorporeal Membrane Oxygenation in Adults: A Systematic Review
22
PubMed. An unbelievable ordeal: The experiences of adult survivors treated with extracorporeal membrane oxygenation
23
PubMed. The History of Extracorporeal Membrane Oxygenation and the Development of Extracorporeal Membrane Oxygenation Anticoagulation
24
PubMed Central. Evolution of extracorporeal membrane oxygenation: historical milestones and advanced developments